Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | FBP1 | P09467 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | EDNRA | P25101 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148204 | 0.85 | CA2 (0.54) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL6920158 | 0.83 | KMT2A (0.69) | KMT2AMEN1ALDH1A1FBP1MAPT | |
| SCHEMBL29547938 | 0.82 | KMT2A (0.67) | KMT2AMEN1ALDH1A1FBP1MAPT | |
| SCHEMBL1087618 | 0.82 | KMT2A (0.67) | KMT2AMEN1ALDH1A1FBP1MAPT | |
| SCHEMBL8224043 | 0.80 | KMT2A (0.65) | KMT2AMEN1ALDH1A1FBP1MAPT | |
| SCHEMBL12520277 | 0.80 | KMT2A (0.65) | KMT2AMEN1ALDH1A1FBP1MAPT | |
| SCHEMBL22446712 | 0.80 | KMT2A (0.65) | KMT2AMEN1ALDH1A1FBP1MAPT | |
| SCHEMBL27784622 | 0.80 | KMT2A (0.65) | KMT2AMEN1ALDH1A1FBP1MAPT | |
| SCHEMBL138127 | 0.79 | KMT2A (0.58) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL11101389 | 0.79 | PTGES2 (0.50) | KMT2AMEN1FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114944467-B | Pole piece and battery comprising same | 珠海冠宇电池股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-116496628-A | Heat insulation composite material and preparation method and application thereof | 百能(天津)能源科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-115873566-A | Bridging plugging material for drilling fluid and preparation method thereof | 中国石油天然气集团有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-114944467-A | Pole piece and battery comprising same | 珠海冠宇电池股份有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-112500051-B | Novel energy-saving environment-friendly foamed light soil for roadbed and preparation method thereof | 广东泰禾建设有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-111689883-B | Synthetic method of diaryl sulfone compound | 上海应用技术大学 | 2022-02-11 | — | — | CN | claimed |
| CN-108144456-B | Preparation of polytetrafluoroethylene hollow fiber membrane, membrane contactor and application | 中国科学院大连化学物理研究所 | 2021-06-04 | — | — | CN | claimed |
| CN-112500051-A | Novel energy-saving environment-friendly foamed light soil for roadbed and preparation method thereof | 广东泰禾建设有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-111689883-A | Synthetic method of diaryl sulfone compound | 上海应用技术大学 | 2020-09-22 | — | — | CN | claimed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | claimed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | claimed |
| US-4102884-A | TREATING A 3,14-DIHYDROXY-CARDENOLIDE WITH OXYGEN AND N-BROMOACETAMIDE IN THE PRESENCE OF PLATINUM, THEN WITH ETHANEDITHIOL, RANEY NICKEL | STEELE CHEMICALS CO. LTD. (CA) | 1978-07-25 | — | — | US | claimed |
| CN-119569658-A | Sulfonyl pyridazinone compound and preparation method and application thereof | 华南师范大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-118073019-B | Intelligent power cable with moistureproof capability and preparation process | 广州岭南电缆股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-114944467-B | Pole piece and battery comprising same | 珠海冠宇电池股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-4134891-A | 14-Functionalized 8,19-oxido steroids and processes for preparation thereof | STEELE CHEMICALS CO. LTD. (CA) | 1979-01-16 | — | — | US | disclosed |
| US-4123532-A | ADMINISTERING A PYRAZOLO(1,5-C)QUINAZOLIN-5(6H)-ONE COMPOUND | E. R. SQUIBB & SONS, INC. (US) | 1978-10-31 | — | — | US | disclosed |
| US-4102884-A | TREATING A 3,14-DIHYDROXY-CARDENOLIDE WITH OXYGEN AND N-BROMOACETAMIDE IN THE PRESENCE OF PLATINUM, THEN WITH ETHANEDITHIOL, RANEY NICKEL | STEELE CHEMICALS CO. LTD. (CA) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | KMT2A 911/4885MEN1 3229/4885ALDH1A1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.